Microenvironment and Immunology Immunosurveillance by Antiangiogenesis : Tumor Growth Arrest by T Cell – Derived Thrombospondin-1

Recent advances in cancer immunotherapy suggest that manipulation of the immune system to enhance the antitumor response may be a highly effective treatment modality. One understudied aspect of immunosurveillance is antiangiogenic surveillance, the regulation of tumor angiogenesis by the immune system, independent of tumor cell lysis. CD4þ T cells can negatively regulate angiogenesis by secreting antiangiogenic factors such as thrombospondin-1 (TSP-1). In tumor-bearing mice, we show that a Th1-directed viral infection that triggers upregulation of TSP-1 in CD4þ and CD8þ T cells can inhibit tumor angiogenesis and suppress tumor growth. Using bone marrow chimeras and adoptive T-cell transfers, we demonstrated that TSP-1 expression in the T-cell compartment was necessary and sufficient to inhibit tumor growth by suppressing tumor angiogenesis after the viral infection. Our results establish that tumorigenesis can be stanched by antiangiogenic surveillance triggered by an acute viral infection, suggesting novel immunologic approaches to achieve antiangiogenic therapy. Cancer Res; 74(8); 2171–81. 2014 AACR.

[1]  E John Wherry,et al.  Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. , 2012, Immunity.

[2]  S. Gregory,et al.  Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C , 2012, Virulence.

[3]  J. Henkin,et al.  Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma. , 2012, Journal of veterinary internal medicine.

[4]  Jacob K. White,et al.  Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1. , 2012, Biophysical journal.

[5]  Ruchi Bansal,et al.  Selective Targeting of Interferon γ to Stromal Fibroblasts and Pericytes as a Novel Therapeutic Approach to Inhibit Angiogenesis and Tumor Growth , 2012, Molecular Cancer Therapeutics.

[6]  J. Lawler,et al.  Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. , 2012, Cold Spring Harbor perspectives in medicine.

[7]  A. Carbone,et al.  Cancers related to viral agents that have a direct role in carcinogenesis: pathological and diagnostic techniques , 2012, Journal of Clinical Pathology.

[8]  Steven A. Rosenberg,et al.  Raising the Bar: The Curative Potential of Human Cancer Immunotherapy , 2012, Science Translational Medicine.

[9]  J. Harford Viral infections and human cancers: the legacy of Denis Burkitt , 2012, British journal of haematology.

[10]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[11]  G. Semenza,et al.  Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 , 2011, Cell.

[12]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[13]  Lin Zhang,et al.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.

[14]  A. J. Mixson,et al.  Vaccines targeting the neovasculature of tumors , 2011, Vascular cell.

[15]  D. Roberts,et al.  Heparan Sulfate Modification of the Transmembrane Receptor CD47 Is Necessary for Inhibition of T Cell Receptor Signaling by Thrombospondin-1* , 2011, The Journal of Biological Chemistry.

[16]  E. Tartour,et al.  Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy , 2011, Cancer and Metastasis Reviews.

[17]  C. Loddenkemper,et al.  Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis , 2011, International journal of cancer.

[18]  Kavya Rakhra,et al.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. , 2010, Cancer cell.

[19]  S. Rosenberg,et al.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. , 2010, The Journal of clinical investigation.

[20]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[21]  H. Fathallah-Shaykh,et al.  A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. , 2010, Archives of Neurology.

[22]  Y. Liu,et al.  A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy. , 2009, Immunology letters.

[23]  I. De Meester,et al.  A CD26-Controlled Cell Surface Cascade for Regulation of T Cell Motility and Chemokine Signals1 , 2009, The Journal of Immunology.

[24]  Yuzhang Wu,et al.  DNA Vaccine Against Tumor Endothelial Marker 8 Inhibits Tumor Angiogenesis and Growth , 2009, Journal of immunotherapy.

[25]  M. Linial,et al.  Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. , 2006, Blood.

[26]  Hao Shen,et al.  An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic Growth , 2003, Cancer biology & therapy.

[27]  J. Lawler,et al.  Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth , 2002, Journal of cellular and molecular medicine.

[28]  C. Hunter,et al.  Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis1 , 2001, The Journal of Immunology.

[29]  N. Ahuja,et al.  Methylation and silencing of the Thrombospondin-1 promoter in human cancer , 1999, Oncogene.

[30]  R. Hynes,et al.  Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.

[31]  S. Groshen,et al.  Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.

[32]  H. Pircher,et al.  A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. , 2003, Cancer research.

[33]  G. Beatty,et al.  IFN-g Can Promote Tumor Evasion of the Immune System In Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen , 2000 .